Hims & Hers Health (HIMS) has accelerated subscriber growth and cross-selling through international expansion and branded GLP-1 partnerships, leading to an increased FY2026 revenue forecast. However, profit margins have declined due to costs from the acquisition of Eucalyptus and expanded GLP-1 offerings. The company's 360 healthcare platform ambitions involve high AI innovation expenses, causing mixed margins expected through FY2027. Despite near-term margin and cash flow challenges, HIMS trades at a relatively low EV/Sales ratio with strong long-term revenue growth potential, maintaining a Buy rating.
Hims & Hers Health (HIMS) has a market cap of $6.70 billion and an enterprise value of $7.40 billion as of October 1, 2026, 09:21 WIB. On Pluang, the stock price is USD 29.93, up 4.29% in the last day, with a high volume of 6,526,891 shares traded. Pluang investors show strong interest, with 99% of order activity on the buy side and a typical hold time of 20 days, indicating active engagement despite margin challenges noted in the news.
